Mode
Text Size
Log in / Sign up
Phase 2 N=183 Randomized Single-blind Treatment

Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment

Substance Use Disorders · Alcohol Abuse · Alcoholism · Substance Dependence · Substance Abuse

Enrolled (actual)
183
Serious AEs
0.0%
Results posted
Oct 2014
Primary outcome: Primary: Abstinence Rate (During the Preceding 90 Days) at 12 Months Follow-up Point as Assessed by the Form-90 — 40; 38; 47; 51 participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Contracting, Prompting and Reinforcement arm (Behavioral); Control arm (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
US Department of Veterans Affairs
Primary completion
Jun 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Abstinence Rate (During the Preceding 90 Days) at 12 Months Follow-up Point as Assessed by the Form-90
40; 38; 47; 51; 55; 49
SECONDARY
Abstinence Rate (During the Preceding 90 Days) at 3- and 6-months Follow-up Point as Assessed by the Form-90
57; 57; 65; 69; 64; 62
SECONDARY
Days Until First Use of Alcohol or Drugs
200.74; 202.43
SECONDARY
Aftercare Attendance
97; 97; 58; 70; 64; 76
SECONDARY
Self-help Support Group Attendance
20.18; 23.44; 18.14; 21.99; 12.41; 14.18
SECONDARY
Days of Substance Abuse (Across the Prior 90 Days)
51; 58; 6; 7; 11; 8
SECONDARY
Rates of Hospitalization (Across the Prior 90 Days)
9.23; 6.87; 1.18; 1.93; 2.14; 4.23

Summary

The Contracts, Prompts, and Social Reinforcement (CPR) intervention was designed to address the continuing care adherence needs of veterans presenting for substance use disorder (SUD) treatment. Final results of our recently completed HSR&D clinical trial suggest CPR meaningfully impacts aftercare adherence and abstinence rates. However, CPR did not impact abstinence rates at earlier follow-up points, other important measures of treatment outcome, or AA/NA support group attendance. Furthermore, the generalizability of CPR to other sites has not been established. Thus, the intervention has been modified and pilot testing of this improved version of CPR, which includes contingent reinforcement of abstinence and improved prompting of AA/NA attendance (CPR+), shows promising results. We are conducting a multi-site randomized clinical trial to examine the effectiveness of CPR+. We recruited 183 veterans seeking residential treatment at the Salem and Jackson VAMCs. Our primary hypothesis is that the CPR group will have higher 1-year abstinence rates compared to the STX group. Our secondary hypotheses are that the CPR will be particularly effective for individuals with co-morbid psychiatric disorders, and that the CPR+ group will remain in AA/NA and in aftercare for a longer duration, have fewer days of substance use, fewer hospitalizations, and lower costs of care. Treatment outcome will be measured 3-, 6-, and 12-months after participants enter treatment and compared to baseline levels. The current study will seek to extend past findings to show longer-term effectiveness of the CPR+ intervention on continuing care adherence and greater impact on treatment outcome. Dissemination and implementation efforts will be ongoing for this brief, inexpensive intervention, which offers an important means to improve participation and outcome for individuals seeking SUD treatment within the VAMC. Data collection and analysis has been completed.

Eligibility Criteria

Inclusion Criteria

Participants were recruited from consecutive veterans who successful complete the 28-day SARRTP at the Salem VAMC and the 21-day SARRTP at the Jackson VAMC. Participants who are uninterested in aftercare, who have unstable housing or other factors that made aftercare participation difficult, will be included to maximize the generalizability of our results.

Exclusion Criteria

Individuals who did not live within a 60-minute drive, and those who did not have transportation and a work schedule allowing attendance of aftercare were ineligible.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00288886). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search